About
Primary antibodies & proteins
Areas of Focus
Categories
Non-PharmaceuticalResearch ProteinAntibodyMidwest
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
0
As Collaborator
5
Total Enrollment
216
By Phase
PHASE1: 5
By Status
COMPLETED: 5
Clinical Trials Pipeline
No trials with date information available
Recent Trials
NCT00000633Collaborator
A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals
PHASE1Completed
55 participants
NCT00000822Collaborator
A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells
PHASE1Completed
46 participants
NCT00000957Collaborator
A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of Accelerated Schedules
PHASE1Completed
30 participants
NCT00000968Collaborator
A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived HIV-1 Recombinant Envelope Glycoprotein (gp160)
PHASE1Completed
60 participants
NCT00001056Collaborator
A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-mcg Dose
PHASE1Completed
25 participants
Locations (1)
Headquarters
Hudson, WI, United States
Map
Loading map...